<DOC>
	<DOCNO>NCT00491569</DOCNO>
	<brief_summary>Both GlyT-1 inhibitor NMDA-glycine site agonist demonstrate beneficial chronic schizophrenia patient . The purpose study compare efficacy safety add-on treatment sarcosine , GlyT-1 inhibitor , D-serine , NMDA-glycine site agonist , chronically stable schizophrenia patient stabilized antipsychotic .</brief_summary>
	<brief_title>Sarcosine D-Serine Add-on Treatment Chronic Schizophrenia</brief_title>
	<detailed_description>The etiology schizophrenia remain unclear . Schizophrenia patient reveal positive symptom , negative symptom , cognitive impairment . In addition dopamine system hyperactivity , hypofunction N-methyl-D-aspartate ( NMDA ) receptor play role pathophysiology schizophrenia . Consequently , enhance NMDA receptor neurotransmission regard novel treatment approach . To date , several report trial NMDA enhancer . Both sarcosine ( N-methylglycine , glycine transporter I inhibitor ) D-serine ( potent NMDA-glycine site agonist ) show therapeutic effect chronically stable patient . Interestingly , sarcosine appear efficacious D-serine acutely exacerbate one added-on antipsychotic . Both sarcosine D-serine yield excellent safety profile . It remain unclear whether sarcosine also efficacious D-serine treatment chronically stable schizophrenia . The aim project examine efficacy safety add-on treatment sarcosine vs. D-serine chronically stable schizophrenia patient stabilized antipsychotic . In study , 60-75 schizophrenic patient recruit 6-week trial randomly assign three group ( 2 gm/d sarcosine , 2 gm/d D-serine , placebo ) double-blind manner . Clinical manifestation ( Positive Negative Syndrome Scale [ PANSS ] , side effect quality life ( QOL ) evaluate every two week trial.. The efficacy three group compare .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<criteria>Fulfill criterion schizophrenia accord Diagnostic Statistic Manual , fourth edition ( DSMIV ) . Agree participate study provide informed consent . Meet DSMIV criterion major mood disorder , current substance dependence mental retardation History epilepsy , head trauma CNS diseases Major , untreated medical disease Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>sarcosine</keyword>
	<keyword>D-serine</keyword>
	<keyword>NMDA</keyword>
</DOC>